FCGR2B and B-cell non-Hodgkin lymphoma: Upon the treatment of B‐cell lymphoma with the commonly used anti‐CD20 antibody rituximab, internalization from the surface of B cells was observed, where the rate of internalization directly correlated with the expression of the inhibitory Fc gamma receptor FcγRIIB (CD32b) in these tumor cells [14, 15].